SISVEL-INTERNATIONAL
14.4.2020 14:27:08 CEST | Business Wire | Press release
Sisvel International S.A. (“Sisvel”) announced today the launch of its “MIOTY” Licensing Platform, a new joint patent licensing effort for the MIOTY technology. The platform has been launched with patents owned, or controlled by, Fraunhofer-Institute for Integrated Circuits IIS (“Fraunhofer IIS”) and Diehl Metering GmbH (“Diehl”).
Fraunhofer IIS and Diehl are working together under the brand name MIOTY in the area of wireless technology for low power wide area networks (“LPWAN”). MIOTY technology is based on the protocol family Telegram Splitting Ultra Narrow band (“TS-UNB”) of the ETSI standard TS 103 357 (“TS-UNB Specification”).
Sisvel is organizing this licensing platform to make MIOTY technology accessible on fair, reasonable, and non-discriminatory terms and conditions by offering a royalty-bearing, non-transferable, non-assignable, non-exclusive license, with no right to grant sublicenses, under patents essential to the TS-UNB Specification. In addition, Sisvel offers a license to patents complementary to MIOTY implementations.
Further information about the terms and conditions of Sisvel’s MIOTY licenses are available on Sisvel’s website https://www.sisvel.com/licensing-programs/wireless-communications/mioty/introduction
. For more details you may contact Sisvel at the following e-mail address MIOTY@sisvel.com
.
The MIOTY Licensing Platform remains open to additional patent owners with relevant patents. Thus, Sisvel invites all parties that have patents or patent applications they believe to be essential to the protocol family TS-UNB of the ETSI standard TS 103 357 to contact Sisvel and submit those patent(s) for an evaluation by the program’s designated, independent evaluators.
About Fraunhofer IIS
The Fraunhofer-Gesellschaft is the leading organization for applied research in Europe. Its research activities are conducted by 74 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of more than 28,000, who work with an annual re-search budget totaling more than 2.8 billion euros.
The Fraunhofer Institute for Integrated Circuits IIS is one of the world’s leading application-oriented research institutions for microelectronic and IT system solutions and services. It is the largest of all Fraunhofer Institutes. Research at Fraunhofer IIS revolves around two guiding topics:
In the area of “Audio and Media Technologies”, the institute has been shaping the digitalization of media for more than 30 years now. Fraunhofer IIS was instrumental in the development of mp3 and AAC and played a significant role in the digitalization of the cinema. Current developments are opening up whole new sound worlds and are being used in virtual reality, automotive sound systems, mobile telephony, streaming and broadcasting.
In the context of “cognitive sensor technologies”, the institute researches technologies for sensor technology, data transmission technology, data analysis methods and the exploitation of data as part of data-driven services and their accompanying business models. This adds a cognitive component to the function of the conventional “smart” sensor.
Nearly 1,100 employees conduct contract research for industry, the service sector and public authorities. Founded in 1985 in Erlangen, Fraunhofer IIS has now 15 locations in 11 cities: Erlangen (headquarters),
Nuremberg, Fürth, Dresden, further in Bamberg, Waischenfeld, Coburg, Würzburg, Ilmenau, Deggendorf and Passau. The budget of 170 million euros is mainly financed by projects. 26 percent of the budget is subsidized by federal and state funds.
Detailed information on: www.iis.fraunhofer.de/en
About Diehl Metering
Diehl Metering is a corporate division of the Diehl Group, headquartered in Nuremberg. With a total annual turnover of 3.75 billion euros, the technology company employs around 17,200 people worldwide. The corporate division Metering supplies solutions for the intelligent use of water, thermal energy, gas and electricity.
Diehl Metering provides smart metering solutions to utilities companies through the intelligent networking of various metering devices into larger data platforms. These solutions offer transparency for utilities and municipalities, and enable considerably increased efficiency in reading, billing and service processes. Diehl Metering’s customers are also able to benefit from real-time effects such as early recognition of leaks and the optimisation of distribution networks through intelligent information regarding prompt adjustment of the offer to suit actual needs.
With Diehl Metering utilities are already perfectly equipped for smart metering as an important component of smart city concepts. Thanks to more than 20 years of experience with the company’s own radio technology, Diehl Metering has at its disposal excellent expertise in communications within the Internet of Things. The MIOTY LPWAN technology has been developed jointly by Fraunhofer IIS and Diehl Metering.
For further information, please visit www.diehl.com/metering
About Sisvel
Sisvel is a world leader in fostering innovation and managing intellectual property. The Group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Founded in 1982, the Group is headquartered in Luxembourg and has subsidiaries in China, Germany, Italy, Japan, Spain, the United States and the United Kingdom. The Group has a long history of managing successful patent portfolios including those related to the audio compression standards known as MP3 and MPEG Audio, as well as broadcasting and receiving of digital terrestrial television standards maintained by the DVB Project. Sisvel currently operates patent pools and joint licensing programs in the fields of mobile communication; wireless local area networking 802.11; digital video broadcasting; recommendation engine and broadband access to data networks.
For additional information, please visit: www.sisvel.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
